Skip to content
Open access · CC-BY via OpenAlex

SENOLYTIC COMBINATION OF DASATINIB AND QUERCETIN: A REVIEW OF PRECLINICAL AND CLINICAL STUDIES

I.I. Morozov, N. N. Molkanov, N. M Kiseleva

Медико-фармацевтический журнал «Пульс» · 2025

Abstract

Societal modernization is driving a steady rise in life expectancy alongside declining birth rates. This demographic transition places a significant burden on social institutions, particularly healthcare systems. Age-related diseases are the leading cause of mortality globally: over 80% of individuals over 65 live with at least one chronic condition, and half of this group suffers from multiple comorbidities. Developing therapeutics that target the fundamental mechanisms of aging is a promising strategy for improving treatment outcomes for age-related diseases and, ultimately, enhancing the quality of life in the elderly. This review aims to present findings from preclinical and clinical studies on the combination of dasatinib and quercetin. It is based on an analysis of literature, primarily international but also including domestic sources, indexed in PubMed and eLibrary databases and retrieved via Google Scholar over the past decade. Analysis of available data suggests that selectively clearing senescent cells (senolysis) is a promising therapeutic strategy for preventing and treating many chronic age-related diseases. However, further research is necessary to confirm the clinical potential of this drug combination, specifically its safety profile, pharmacokinetics, and pharmacodynamics. Additionally, there is an urgent need to identify relevant and reliable biomarkers to objectively assess the efficacy of senolytic therapies. Keywords: celluar senescence(definition); senolytics(definition); dasatinib; quercetin; SASP.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.26787/nydha-2686-6838-2026-28-1-49-58
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Morozov, I., Molkanov, N.N., &amp; Kiseleva, N.M. (2025). SENOLYTIC COMBINATION OF DASATINIB AND QUERCETIN: A REVIEW OF PRECLINICAL AND CLINICAL STUDIES. <em>Медико-фармацевтический журнал «Пульс»</em>. https://doi.org/10.26787/nydha-2686-6838-2026-28-1-49-58
Vancouver
Morozov I, Molkanov NN, Kiseleva NM. SENOLYTIC COMBINATION OF DASATINIB AND QUERCETIN: A REVIEW OF PRECLINICAL AND CLINICAL STUDIES. Медико-фармацевтический журнал «Пульс». 2025. doi:10.26787/nydha-2686-6838-2026-28-1-49-58.
BibTeX
@article{ii2025SENOLY, title = {SENOLYTIC COMBINATION OF DASATINIB AND QUERCETIN: A REVIEW OF PRECLINICAL AND CLINICAL STUDIES}, author = {I.I. Morozov and N. N. Molkanov and N. M Kiseleva}, journal = {Медико-фармацевтический журнал «Пульс»}, year = {2025}, doi = {10.26787/nydha-2686-6838-2026-28-1-49-58}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings